Effer-K Orange (potassium bicarbonate) NDC 51801-001

NDC codes

FDA NDC Directory

Product NDC (as listed)51801-001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51801-0001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51801-001-30	51801000130	30 POUCH in 1 CARTON (51801-001-30) / 1 TABLET, EFFERVESCENT in 1 POUCHMarketed from Jan 30, 2013
51801-001-40	51801000140	100 POUCH in 1 CARTON (51801-001-40) / 1 TABLET, EFFERVESCENT in 1 POUCHMarketed from Jan 30, 2013

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Effer-K OrangeSuffix: Orange
Generic name (nonproprietary): potassium bicarbonate
Active ingredients: Potassium bicarbonate — 977.5 mg/1
Dosage form: Tablet, Effervescent
Route: Oral
Labeler: Nomax Inc.
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Jan 30, 2013
Listing expires: Dec 31, 2026
Identifiers: Product ID 51801-001_de8efd5c-a055-462d-a104-5bca4773fe0cSPL ID de8efd5c-a055-462d-a104-5bca4773fe0cSPL set ID bd402d91-d28d-49e9-9c1d-0983854773b3RxCUI 1088772, 1088774UNII HM5Z15LEBN

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451801000130 followed by a unit qualifier and the quantity

Package 51801-0001-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 23, 2019.

Indications (excerpt from the label)

Indications and Usage For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certa…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)